Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis

Table 2

Cell cycle analysis of marrow samples.

	S (%)		G2 (%)		M (%)
	Controls	MDS	Controls	MDS	Controls	MDS
nRBC	27.9 (16.2–41.9)	31.2 (12.8–56.4)	4.7 (2.1–8.2)	6.3 (1.1–17.0)	1.1 (0.5–1.6)	1.0 (0.01–3.6)
Myeloid	16.0 (6.7–28.1)	17.16 (7.8–32.1)	1.6 (0.0–3.3)	4.3 (0.2–11.5)	0.32 (0.2–0.6)	0.45 (0.0–1.1)
CD34+	13.5* (7.4–22.9)	10.9* (2.0–16.0)	*	*	0.6 (0.2–1.1)	0.8 (0.1–2.3)

Controls (𝑛=20), MDS (𝑛=19).
Cell populations discriminated by CD45, SS, CD71, and CD34.
DNA content assessed using DRAQ5; mitoses assessed using MPM-2.
Results expressed as mean (%) positive (range).
*Because of infrequent stem cell events, S and G2 are combined as post-G1 for stem cells.